Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials

scientific article published on 10 February 2016

Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2016PLoSO..1146465M
P356DOI10.1371/JOURNAL.PONE.0146465
P932PMC publication ID4749572
P698PubMed publication ID26863139
P5875ResearchGate publication ID293827425

P50authorFranz KönigQ40096364
Martin PoschQ42321315
P2093author name stringThomas Jaki
Dominic Magirr
P2860cites workAdaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines AgencyQ26824359
A practical simulation method to calculate sample size of group sequential trials for time-to-event data under exponential and Weibull distributionQ28483447
Modification of the sample size and the schedule of interim analyses in survival trials based on data inspectionsQ30669416
The reassessment of trial perspectives from interim data--a critical viewQ31010971
Adaptive trial design: a general methodology for censored time to event dataQ33398428
Biomarker driven population enrichment for adaptive oncology trials with time to event endpointsQ35226583
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 studyQ36770191
Adaptive designs for confirmatory clinical trialsQ37389417
Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.Q38380750
Adaptive seamless designs with interim treatment selection: a case study in oncologyQ41498564
An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpointsQ44262116
A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint informationQ45374094
Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncologyQ46054107
A conditional error function approach for subgroup selection in adaptive clinical trialsQ46406244
Mid-course sample size modification in clinical trials based on the observed treatment effectQ47172162
Adaptive sample size calculations in group sequential trialsQ47213254
Flexible two-stage design with sample size reassessment for survival trialsQ47283214
Adaptive increase in sample size when interim results are promising: a practical guide with examplesQ47342519
Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections, by H. Schäfer and H.-H. Müller, Statistics in Medicine 2001; 20: 3741-3751.Q47422901
Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosisQ48152166
When is a seamless study desirable? Case studies from different pharmaceutical sponsorsQ50116411
Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.Q51911840
Evaluation of experiments with adaptive interim analyses.Q52364596
Properties of proportional-hazards score tests under misspecified regression modelsQ70778836
Designed extension of studies based on conditional powerQ70971455
Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approachesQ74497643
Planning and analyzing adaptive group sequential survival trialsQ80261915
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue2
P407language of work or nameEnglishQ1860
P921main subjecthypothesis testingQ110783625
P304page(s)e0146465
P577publication date2016-02-10
P1433published inPLOS OneQ564954
P1476titleSample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials
P478volume11

Reverse relations

cites work (P2860)
Q47676741Adaptive designs for the one-sample log-rank test.
Q59336746Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency
Q59136188Applicability and added value of novel methods to improve drug development in rare diseases
Q53281780Bias, Operational Bias, and Generalizability in Phase II/III Trials.
Q54941922Lessons learned from IDeAl - 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials.
Q47574086Optimized adaptive enrichment designs
Q38630899Sample size adjustment designs with time-to-event outcomes: A caution

Search more.